Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. - Wikidata - wikimedia - TriplyDB

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

http://www.wikidata.org/entity/Q42603658

about

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives Chemotherapy in Premenopausal Breast Cancer Patients Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients Bisphosphonates in breast cancer The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy Bisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Immune regulation of bone metastasis Bone-Targeted Therapy Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo Status of adjuvant endocrine therapy for breast cancer.Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Aromatase inhibitors-induced bone loss in early breast cancer.The microenvironment matters: estrogen deficiency fuels cancer bone metastases Correlation of mammographic density and serum calcium levels in patients with primary breast cancer Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer.Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer Management options of breast cancer related osteoporosis.Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.Factors associated with pregnancy attempts among female young adult cancer survivors Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol.Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.Zoledronic acid in breast cancer: latest findings and interpretations

P2860

Q21132670-057A17FB-9E14-482C-909F-6951C9DFC64E Q26773012-6A5A2E53-2E77-49AE-8705-FA2A974B78B8 Q26774622-1F3C3E3A-52AA-4BD1-8AEC-3D9FF6B07FF0 Q26783705-FBD23BB8-16D2-4AA3-8BD8-166AD2E61FDB Q26824762-B2E2C1D5-3C28-4682-BFD7-809C67480384 Q26859326-7ED963B5-7653-4189-A52C-48529F11344D Q26859775-FEC684BB-1479-4DD7-BD7A-5AB9AF820074 Q26861586-A2A99EA2-1836-4193-A9C8-900CB488AD45 Q26861745-8A3A5103-7685-4E27-84A6-88850AEEC526 Q27002430-268D1AE3-4125-45B3-B6F2-FC7201F6D0BF Q27005871-18E61C6C-0F5A-4B3D-9A8B-9E4591BCA7DF Q28081294-11D37A5F-588A-4358-8963-348794F26BA0 Q28081996-7AAE7172-26AC-44C0-98CF-CF29CCC095A9 Q28551320-1CF6B216-03D8-486F-B23D-1A73AF0B9904 Q30275126-C9862618-1A4A-490F-B967-61D184B7D8CB Q30543788-ADF40E55-C3F5-4BC6-B8AA-5D8ECE5D5BBA Q31150676-18BE07B6-83EE-4CCF-9B2C-90B87FA054D8 Q33560459-1707B9F7-25BD-4CFF-BD04-9045A67E0B30 Q33587199-5D04EC47-18AA-4FF7-8CED-FAD19CF4568D Q33692900-35A2B21F-5765-4B1D-A587-B4DD47163401 Q33739138-B3E18C55-1811-4006-8D78-D9FB1667CE30 Q33739204-4A548149-42BD-4D59-BED7-B0F677946552 Q33752867-6E0AD4E0-BED1-4012-B7E4-C0D1CE5BE4DE Q33772299-DE94FDB6-306D-40F5-A194-D0E87189545A Q33775316-1206DFF9-25D2-49D7-8680-F8FD1DB8A6FF Q33920919-B191F5D9-BD79-4933-AC31-9EE537BB0ACA Q34042715-BF57D906-518B-4874-962F-7729A2D74321 Q34113489-4CDA1930-41EE-4ED8-B19C-D6FE3546E77A Q34127953-2FDFAD0C-8B76-476B-9338-AF4848A5EA90 Q34174466-BC8B26D4-AEEC-49FD-8B38-C49BB9B68BFC Q34230292-F1BA5938-6560-44C3-85BA-1B8B52E17F9D Q34245992-D813863C-B3F1-448D-BE55-597C5BD1B983 Q34348233-862616FF-275F-4BAF-9DBD-39C8B477F2BC Q34459691-AEC3CFF6-A6F9-42EC-9F5A-36093049B776 Q34581699-8100698A-D363-4E37-AF40-0C74C9B05904 Q34583705-A49D4988-546E-429B-81CB-8F47A9957D10 Q34611626-BCEFBF64-89CB-4490-8920-280D8EFE4257 Q35073191-9894BEA0-6600-4080-8E2B-4CF6DC08ACBA Q35431110-7E3E776A-0D4F-45A2-A88D-142E43FA616C Q35534524-E7648ADF-8BE3-495D-9BA9-9662EE589832

P2860

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

http://www.wikidata.org/entity/Q42603658

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.

@en

Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.

@nl

type

label

Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.

@en

Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.

@nl

prefLabel

Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.

@en

Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial.

@nl

P1433

Q42603658-80382C00-5D82-4557-A71E-2C14C8E72CBE

P1476

Q42603658-CFE1206F-C532-4DB1-909F-71F0FEC6EDB4

P2093

Q42603658-077D7669-4131-41B9-870E-DC9C40245576

Q42603658-1A9C20BF-E2E4-4C0E-9CB5-9F76588543A4

Q42603658-2210D616-EC6D-4B99-93BD-E2D8A8BB31F1

Q42603658-2550428B-544E-49E3-942E-59D6FA7F5400

Q42603658-462D8431-20D7-493F-8983-E13DF28B70DA

Q42603658-4AF9934C-9AFE-495B-8B5A-AE9D3E2B16F2

Q42603658-6A3352C0-ED12-494B-B943-A7AC2215A7C0

Q42603658-6A9FFDFB-188A-4EA5-B35D-0F06C5119F68

Q42603658-918B7DCF-3DB8-4400-8DC6-CEE817D24E0E

Q42603658-9492A6A6-FA34-43AB-AE5A-BA02FE840A74

P304

Q42603658-FA1C36AC-9082-4FC5-8798-30D4240D7CEC

P31

Q42603658-2DDACD7B-6614-4D5E-B326-00265A75D371

P356

Q42603658-7E48FD25-B3B0-496F-BDBF-C7A11E9D23F9

P433

Q42603658-97C6C681-8EF4-4949-8106-EC51A40E00EF

P478

Q42603658-4426948B-84F7-43BC-B9F4-F3C18CC72F9B

P50

Q42603658-565BFFDE-C8BA-4779-B05E-7FE5D6582604

P577

Q42603658-5A9B4ACE-6A9E-470E-B2E8-1CEDCDEF09DD

P5875

Q42603658-95A30877-74E4-4006-97C5-9546499E68FB

P698

Q42603658-2D49E4C1-6353-40AC-88A7-0A4B619BF63C

P356

S1470-2045(11)70122-X

P1433

The Lancet Oncology

P1476

Adjuvant endocrine therapy plu ...... the ABCSG-12 randomised trial

@en

P2093

Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria

http://www.w3.org/2001/XMLSchema#string

Brigitte Mlineritsch

http://www.w3.org/2001/XMLSchema#string

Christian Fesl

http://www.w3.org/2001/XMLSchema#string

Christian Menzel

http://www.w3.org/2001/XMLSchema#string

Dietmar Heck

http://www.w3.org/2001/XMLSchema#string

Ernst-Pius Forsthuber

http://www.w3.org/2001/XMLSchema#string

Gerhard Hochreiner

http://www.w3.org/2001/XMLSchema#string

Gero Luschin-Ebengreuth

http://www.w3.org/2001/XMLSchema#string

Guenther Steger

http://www.w3.org/2001/XMLSchema#string

Gunda Pristauz

http://www.w3.org/2001/XMLSchema#string

P304

631-641

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(11)70122-X

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51192156

http://www.w3.org/2001/XMLSchema#string

P698

21641868

http://www.w3.org/2001/XMLSchema#string